Validation of ion mobility spectrometry - mass spectrometry as a screening tool to identify type II kinase inhibitors of FGFR1 kinase.
Helen S BeestonTobias KleinRichard A NormanJulie A TuckerMalcolm AndersonAlison E AshcroftGeoffrey A HoldgatePublished in: Rapid communications in mass spectrometry : RCM (2021)
A robust ESI-IMS-MS method has been implemented to distinguish between the binding mode of type I and type II inhibitors by monitoring the conformational unfolding profile of FGFR1. This rapid method requires low sample concentrations and could be used as a high-throughput screening technique for the characterisation of novel kinase inhibitors.